劇症肝炎の内科的治療システム(<特集>劇症肝炎の治療をめぐって)

概要

論文の詳細を見る
Therapeutic systems for fulminant hepatitis are reviewed. One system is an artificial liver support system which can reliably sustain patient life until recovery. For this purpose, we developed a treatment that combines plasma exchange and hemodiafiltration using high-performance membranes with protein passing large pores. The efficacy of the system has been widely recognized, and 80% of the major hospitals in Japan have already adopted the system. The other system is a treatment system for underlying liver diseases which can lead to persistent and chronic liver destruction such as HBV carriers developing fulminant hepatic failure, type C, and type non-A〜non-G. For this purpose, antivirals in combination with immunosuppressive agents are administered, resulting in a sharp fall in transaminase accompanied by rapid recovery of liver function. In order to obtain a high survival rate, the prediction of fulminant hepatitis during the stage of acute hepatitis and early initiation of treatment for hepatitis is mandatory.
日本アフェレシス学会の論文
2003-10-31